Motion Sickness Relief (dimenhydrinate)

For the prevention of motion sickness, dimenhydrinate should be taken orally 30 minutes before exposure to motion. For the prevention and treatment of nausea, vomiting, and/or vertigo associated with motion sickness, the usual oral dosage of dimenhydrinate for self-medication in adults and children 12 years of age or older is 50-100 mg every 4-6 hours, not to exceed 400 mg in 24 hours, or as directed by a clinician. The same dosage can be given parenterally in adults to treat motion sickness. Children 6 to younger than 12 years of age may receive 25-50 mg orally every 6-8 hours, not to exceed 150 mg in 24 hours, or as directed by a clinician. Children 2 to younger than 6 years of age may receive 12.5-25 mg orally every 6-8 hours, not to exceed 75 mg in 24 hours, or as directed by a clinician. Alternatively, children may be given 1.25 mg/kg or 37.5 mg/m2, orally or IM 4 times daily, up to a maximum of 300 mg daily. Children younger than 2 years of age should receive oral dimenhydrinate only under the direction of a clinician. IV dosage has not been established for children.

For symptomatic relief of Meniere's disease, 25-50 mg of dimenhydrinate has been given orally 3 times daily for maintenance, or 50 mg has been given IM for acute attacks.

Dimenhydrinate may be administered orally or by IM or IV injection. For IV injection, each 50 mg of dimenhydrinate must be diluted with 10 mL of 0.9% sodium chloride injection and administered slowly over a period of 2 minutes.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

Reproduction studies in rats and rabbits using dimenhydrinate doses up to 20 and 25 times the human dose (on a mg/kg basis), respectively, have not revealed evidence of harm to the fetus. There are no adequate and well-controlled studies using dimenhydrinate in pregnant women. Clinical studies to date in pregnant women receiving the drug have not indicated an increased risk of abnormalities when administered during any trimester. Although the possibility of harm to the fetus appears remote, dimenhydrinate should be used during pregnancy only when clearly needed.

Small amounts of dimenhydrinate are distributed into milk. Because of the potential for adverse reactions to dimenhydrinate in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.

No enhanced messaging available.